LXRX Q4 2023 Earnings — Lexicon Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

LXRXLexicon Pharmaceuticals, Inc.

$704M

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$702,000+2407.1% YoY

Gross Profit

-$14M-2012.8% margin

Operating Income

-$47M-6657.7% margin

Net Income

-$50M-7087.7% margin

EPS (Diluted)

$-0.20

QoQ Revenue Growth

+333.3%

Cash Flow

Operating Cash Flow

-$51M

Free Cash Flow

-$51M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$229M

Total Liabilities

$136M

Stockholders' Equity

$93M

Cash & Equivalents

$22M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$702,000	$28,000	+2407.1%
Gross Profit	-$14M	-$75,000	-18740.0%
Operating Income	-$47M	-$30M	-54.4%
Net Income	-$50M	-$30M	-63.2%